SCHEMBL7152196

SCHEMBL7152196

COc1ccc2nc(SCCCS(=O)(=O)Nc3ccccc3C)sc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.49
LMNA P02545 5/20 0.49
ALDH1A1 P00352 4/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
PDK1 Q15118 1/20 0.46
PKM P14618 1/20 0.44
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NPC1 O15118 1/20 0.42
NFKB1 P19838 1/20 0.42
RAB9A P51151 1/20 0.42
GFER P55789 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PIK3CG P48736 2/20 0.42
CTSL P07711 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151731 0.97 MAPT (0.48) MAPTLMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL7154156 0.94 MAPT (0.48) MAPTLMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL7151765 0.91 MAPT (0.52) MAPTLMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL7149643 0.88 PDK1 (0.50) MAPTLMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL7149243 0.88 MAPT (0.51) MAPTLMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL7151670 0.86 LMNA (0.65) MAPTLMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL7150052 0.85 PDK1 (0.51) MAPTLMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL7149130 0.85 MAPT (0.53) MAPTLMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL7148790 0.85 MAPT (0.50) MAPTLMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL7150971 0.85 MAPT (0.52) MAPTLMNAL3MBTL1SMN1; SMN2PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 MAPT 3839/4885LMNA 1481/4885ALDH1A1 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.